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Abstract
Background: After antibiotic treatment of Lyme borreliosis, a subset of patients report persistent symptoms, also
referred to as post-treatment Lyme disease syndrome. The reported prevalence of persistent symptoms varies
considerably, and its pathophysiology is under debate. The LymeProspect study has been designed to investigate
the prevalence, severity, and a wide range of hypotheses on the etiology of persistent symptoms among patients
treated for Lyme borreliosis in the Netherlands.
Methods: LymeProspect is a prospective, observational cohort study among adults with proven or probable Lyme
borreliosis, either erythema migrans or disseminated manifestations, included at the start of antibiotic treatment.
During one year of follow-up, participants are subjected to questionnaires every three months and blood is
collected repeatedly during the first three months. The primary outcome is the prevalence of persistent symptoms
after treatment, assessed by questionnaires online focusing on fatigue (CIS, subscale fatigue severity), pain (SF-36,
subscale pain) and neurocognitive dysfunction (CFQ). Potential microbiological, immunological, genetic,
epidemiological and cognitive-behavioral determinants for persistent symptoms are secondary outcome measures.
Control cohorts include patients with long-lasting symptoms and unconfirmed Lyme disease, population controls,
and subjects having reported a tick bite not followed by Lyme borreliosis.
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Discussion: This article describes the background and design of the LymeProspect study protocol. This study is
characterized by a prospective, explorative and multifaceted design. The results of this study will provide insights
into the prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis, and may provide
a rationale for preventive and treatment recommendations.
Trial registration: NTR4998 (Netherlands Trial Register). Date of registration: 13 February 2015.
Keywords: Lyme disease, Borreliosis, Erythema Migrans, Borrelia, Persistent symptoms, Post-treatment Lyme disease
syndrome, Study protocol
Background
Lyme borreliosis is caused by tick-borne Borrelia burgdor-
feri sensu lato genospecies. The incidence of tick bites and
cases of Lyme borreliosis has increased substantially over
the past decades. In the Netherlands, annually over one
million people report a tick bite, and more than 25.000
cases of Lyme borreliosis are diagnosed [1–3]. The most
common manifestation of Lyme borreliosis in Europe is
erythema migrans, a red or bluish-red expanding skin le-
sion arising within days to weeks at the site of the tick
bite. A minority of infected individuals develops dissemi-
nated Lyme borreliosis, of which Lyme neuroborreliosis,
Lyme arthritis and acrodermatitis chronic atrophicans
(ACA) are most common [4].
Although Lyme borreliosis generally responds well to
antibiotic therapy, some patients report persistent symp-
toms after treatment. However, the prevalence of persist-
ent symptoms in literature varies considerably, between
0 and 48% [2, 5–17], and many of these studies lack
proper controls. Case definition, Lyme borreliosis mani-
festation, follow-up, geographic location, and delay be-
tween onset of symptoms and treatment might explain
the divergence in prevalence. Whereas the initial object-
ive manifestation usually resolve, disabling symptoms
such as fatigue, musculoskeletal pain and neurocognitive
disturbances can last for months or even years, greatly
affecting quality of life. When present for more than six
months, post-treatment Lyme Disease Syndrome
(PTLDS) is the term frequently used to describe these
persistent symptoms [9, 18, 19].
The prevalence as well as the underlying pathology of
persistent symptoms after treatment for Lyme borreliosis
are not clearly defined and under debate. Consequently,
uniform guidelines on prevention and treatment of per-
sistent symptoms are lacking. These uncertainties have
led to great societal concern and dissatisfaction among
patients. A broad range of hypotheses exists regarding
the pathophysiology underlying persistent symptoms,
ranging from microbiological, immunological, genetic,
cognitive-behavioral, clinical, to epidemiological explana-
tions. The LymeProspect study has been designed to test
this broad range of hypotheses on persistent symptoms
in a large cohort of patients with confirmed Lyme
borreliosis. In this prospective, observational study, pa-
tients are followed from the start of antibiotic treatment
during one year. This design allows us to assess the
prevalence of persistent symptoms after treatment for
Lyme borreliosis and to identify determinants of these
symptoms. In this paper, we describe the study protocol
in detail.
Methods
Study design
A multi-center prospective, observational cohort study
with one year of follow-up is performed to determine
the prevalence and severity of persistent symptoms after
antimicrobial treatment for active Lyme borreliosis, and
to assess determinants for development of these symp-
toms. Potential microbiological, immunological, genetic,
clinical, cognitive-behavioral, and epidemiological deter-
minants are assessed in patients with confirmed early or
disseminated Lyme borreliosis. This study is a collabor-
ation between the Dutch National Institute for Public
Health and the Environment (RIVM, Bilthoven, the
Netherlands) and the clinical expert centers for Lyme bor-
reliosis at Amsterdam UMC (location AMC, University of
Amsterdam, Amsterdam, the Netherlands), and Radboud
university medical center (Radboudumc, Nijmegen, the
Netherlands), in collaboration with the Lyme center Apel-
doorn (Gelre Hospital, Apeldoorn, the Netherlands). The
study has been approved by the medical ethics committee
(METC) Noord-Holland (NL50227.094.14), and is con-
ducted according to the principles of the Declaration of
Helsinki.
Study population
This prospective study comprises adults with probable
or proven Lyme borreliosis - either local infection or dis-
seminated disease - in the Netherlands. Recruitment has
started in April 2015. Recruitment of children has
started in 2017 and results will be reported separately.
Case definitions include clinical and laboratory criteria,
and are largely based on the case definitions established
by ESGBOR (Additional file 1: Table S1) [4]. Patients are
included within 7 days after, but preferably before, initi-
ation of antibiotic treatment. Patients with signs and
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symptoms attributed to a previous episode of Lyme bor-
reliosis are excluded (Table 1). A separate cohort of pa-
tients with long-lasting symptoms attributed to Lyme
borreliosis, without clinical and microbiological confirm-
ation, is enrolled in the unconfirmed Lyme borreliosis
control group. Inclusion criteria in this control group in-
clude symptoms (e.g. fatigue, cognitive complaints, my-
algias and arthralgias) for more than 6months with a
severity above the Dutch norm score, as assessed by a
combined questionnaire based on the CIS, SF-36 and
CFQ as described below; negative serology (B. burgdor-
feri s.l. IgG ELISA or a combined IgM/IgG ELISA); and
attribution of symptoms to Lyme borreliosis either be-
cause symptoms originated within one month after a
documented tick bite, or because of a positive result of a
non-recommended test (e.g., LTT or other commercially
available cellular test, CD57 analysis) (Table 1). In
addition, two other control cohorts are available for
comparison. Firstly, a population control cohort consists
of subjects randomly recruited nationwide, representing
the general population. Data from patients and from
these controls are matched by age, gender, geographical
region, and month of enrollment. Secondly, a tick bite
control cohort includes subjects who have reported a
tick bite without having developed clinical evidence for a
Borrelia infection at baseline or during follow-up. The
same questionnaires are administered to individuals in
all control cohorts and the prospective study patients
during one year of follow-up.
Recruitment, inclusion and follow-up of participants
Recruitment, inclusion and follow-up of participants
occur both online and at the clinical expert centers for
Lyme borreliosis. The national website www.tekenradar.
nl offers secure eligibility screening, inclusion and
follow-up of participants with confirmed Lyme borrelio-
sis after either self-registration or registration by a med-
ical doctor (GP or specialist). After online enrollment,
the participant’s medical doctor is contacted to confirm
the diagnosis. Written informed consent is obtained
from eligible patients. After inclusion, blood collection
tubes are delivered at the patient’s home address by
courier service, and blood is collected at a local blood
draw service at baseline and after 6 weeks. Blood sam-
ples are sent overnight to the study laboratories and
processed immediately upon arrival, to ensure the pro-
cessing is completed within 24 h after blood collection.
In addition to online enrollment, study subjects as well
as unconfirmed Lyme borreliosis controls are enrolled at
the participating clinical expert centers. For these pa-
tients, blood samples are collected and processed imme-
diately after inclusion. From a subset of patients with
skin manifestations, skin biopsies are obtained after add-
itional informed consent.
Measurements
For patients with confirmed Lyme borreliosis, standard
demographical characteristics are reported at baseline,
including gender, age, and highest educational level. Co-
morbidities are reported at baseline, and new medical
diagnoses are evaluated during follow-up. Details on ex-
posure to ticks, previous Lyme borreliosis episodes and
the current Lyme borreliosis manifestation and treat-
ment are collected. Patients with erythema migrans or
other skin manifestations, who are included online are
requested to upload a photograph of their skin lesion,
for blinded evaluation by independent experts. Signs and
symptoms are assessed at baseline and after 3, 6, 9 and
12months, by online questionnaires on fatigue, pain and
neurocognitive dysfunction (Table 2). Fatigue severity is
Table 1 Inclusion and exclusion criteria
Patients with confirmed Lyme borreliosis
Inclusion criteria:
• Patients ≥18 years with confirmed proven or probable early localized
or disseminated Lyme borreliosis manifestation as specified in
Additional file 1: Table S1;
• In case of an EM reported at www.tekenradar.nl, the EM has been
present < 3months and the clinical diagnosis has been confirmed
by the general practitioner (criteria for clinical diagnosis are
described in Additional file 1: Table S1);
• Subjects live or stay on the mainland of the Netherlands.
Exclusion criteria:
• Subjects unable to provide informed consent or not having a
sufficient command of the Dutch language;
• Subjects who started antibiotic treatment > 4 days before inclusion
(for subjects included through the website www.tekenradar.nl) or >
7 days before inclusion (for subjects included through the clinical
expert centers for Lyme borreliosis);
• Subjects who have ongoing signs or symptoms attributed to a
previous episode of Lyme borreliosis.
Patients with unconfirmed Lyme borreliosis
Inclusion criteria:
• Myalgia, arthralgia, neuralgia, concentration disorders, cognitive
disturbances, with or without fatigue, present for ≥6 months at
baseline
• Severity of symptoms assessed by the CIS, SF-36 and/or CFQ
questionnaire above the Dutch norm scores;
• Subjects have a negative serological test for B. burgdorferi s.l. (IgG
ELISA or C6 IgM/IgG ELISA), but have a history of an unconfirmed
suspicion of Lyme disease, based on
• a positive result for a non-recommended diagnostic test (e.g.,
cellular tests, CD57 analysis, viable blood analysis,
bioresonance), or
• onset of disease symptoms that have started within one month
after a documented tick bite.
Exclusion criteria:
• Subjects are unable to give informed consent or do not have
sufficient command of the Dutch language.
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assessed by the fatigue severity subscale of the Checklist
Individual Strength (CIS) [20]. Scores range from 8 to
56, and scores of 35 or higher reflect severe fatigue. The
Medical Outcomes Survey Short Form-36 (SF-36) pain
subscale is used to assess severity and impact of pain.
Significant impairment due to pain is reflected by a
score of 55 or lower, based on Dutch norm scores [21].
Neurocognitive functioning is assessed with the Dutch
version of the Cognitive Failure Questionnaire (CFQ)
[22]. Clinically significant complaints on neurocognitive
functioning are reflected by a score of 44 or higher.
Clinical and cognitive-behavioral parameters are
assessed by online questionnaires as well, including som-
atic symptoms (PHQ-15) [23], physical and social func-
tioning (SF-36, subscales physical functioning and social
functioning) [24], health care use, absenteeism from
work, co-morbidity (adapted from TiC-P) [25],
pre-existent symptoms (adapted from PREDIS) [26], ill-
ness perception (Brief IPQ) [27], cognitive and behav-
ioral responses to symptoms (CBRSQ) [28],
psychological distress (HADS) [29], self-efficacy with re-
spect to pain and fatigue (SES, PCS) [30, 31], and the
Table 2 Data collection and measurements for all patients with confirmed Lyme borreliosis
Baseline 10
days
2
weeks
6
weeks
3
months
6
months
9
months
12
months
Written information and informed consent X
Baseline characteristics X
Physical examination Xa Xac Xac Xac Xac
Recording Lyme manifestation, treatment and concomitant
medication
X Xb X X X X
Recording adverse events X Xb X X Xa
Questionnaires
Primary outcome: CIS (subscale fatigue),
SF-36 (subscale pain), CFQ
X X1 X X1 X
Clinical parameters: PHQ-15, SF-36 (subscale
physical functioning and subscale social
functioning), TiC-P (health-care use and
absenteeism of work)
X X X X X
Cognitive-behavioral parameters: brief IPQ,
CBRSQ, HADS, SES-F, PCS, IPAQ
X X X
Comorbidities: TiC-P (co-morbidity list) X X
Comorbidities: PREDIS X
Laboratory measurements
B. burgdorferi s.l. serology X Xac X Xac
Serology other TBPs3 X2 X2
PCR B. burgdorferi s.l. and other TBPs3 (blood) X X
Genome wide association studies X4
Cytokine measurements in cell culture supernatants X X
Gene expression micro-arrays on ex vivo stimulated PBMCs X5 X5
Skin biopsies: culture, MLST, PCR B. burgdorferi s.l. and
other TBPs, gene-expression profiling
X6
aPatients included through the clinical expert centers for Lyme borreliosis only
bPatients included through the website www.tekenradar.nl only
cThese visits and laboratory measurements can be left out if patients are not able or not willing to. This is regarded as an allowed deviation from the protocol
1CIS questionnaire only short version, to limit the burden for patients
2In cases (patients with persistent symptoms) and twice as much controls (patients without persistent symptoms), starting with the 6 weeks sample. If borderline
or positive, the baseline sample will be tested as well
3Serology on Babesia spp., Rickettsia conorii, Anaplasma phagocytophilum (commercially available) and Borrelia miyamotoi (experimental). Quantitative PCR
including Babesia spp., Rickettsia spp., Anaplasma phagocytophilum, Neoehrlichia mikurensis, as well as a pan relapsing fever Borrelia qPCR (if positive, a specific
Borrelia miyamotoi qPCR will be performed)
4In the first consecutive included 600 patients with erythema migrans
5In a selection of patients, included through the clinical expert centers for Lyme borreliosis
6In patients with a skin manifestation included through the clinical expert centers for Lyme borreliosis (only after additional consent). Both the affected and
contra-lateral side will be investigated
Abbreviations: (q)PCR (quantitative) polymerase chain reaction, TBPs tick-borne pathogens, PBMCs peripheral blood mononuclear cells, MLST Multilocus sequence
typing. For the abbreviations of the various questionnaires, see the main text
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level of physical activity (IPAQ) [32] (Table 2). Blood is
collected at several time points for microbiological, im-
munological and genetic analyses (Table 2). For detec-
tion of B. burgdorferi s.l.-specific antibodies, a total Ig
C6 ELISA (Immunetics, Boston, MA, USA) is performed
on all samples, followed by IgM and IgG immunoblot
analysis (Mikrogen GmbH, Neuried, Germany) for con-
firmation of C6 ELISA positive or borderline results.
Furthermore, serology for other tick-borne pathogens is
performed on at least all samples collected at six weeks.
Immunofluorescence analysis (Focus Diagnostics, Cy-
press, CA, USA) is used for the detection of antibodies
directed to Babesia spp., Rickettsia spp. and Anaplasma
phagocytophilum. An IgM and IgG ELISA (TestLine
Clinical Diagnostics, Brno, Czech Republic) for tick
borne encephalitis (TBE) virus is conducted for patients
with persistent symptoms and matched patients without
persistent symptoms. Antibodies against B. miyamotoi
are assessed by an experimental assay [33]. All blood
samples are analyzed with (multiplex) real-time PCRs,
based on various genes specific for B. burgdorferi s.l., B.
miyamotoi, A. phagocytophilum, Candidatus Neoehrli-
chia mikurensis, spotted fever Rickettsia’s, Bartonella
spp., and a wide range of Babesia spp.. In patients with
cutaneous Lyme borreliosis manifestations, skin biopsies
are collected at baseline after additional consent, and
assessed for B. burgdorferi s.l. culture and molecular de-
tection of B. burgdorferi s.l. by PCR. Multilocus se-
quence typing (MLST) analysis is performed to type
clinical B. burgdorferi s.l. isolates from skin biopsies.
Immunological assays include measurements of pro-
and anti-inflammatory cytokines in cell culture superna-
tants of ex vivo stimulated whole blood and PBMCs, stim-
ulated with RPMI (medium control), viable B. burgdorferi
s.l. (mix of B. burgdorferi s.s., B. garinii and B. afzelii) at
different multiplicities of infection (MOI), lipopolysac-
charide (LPS), Pam3cys, and heat killed Candida albicans
blastoconidia. Interleukin (IL)-1ß, IL-6, IL-1Ra and IL-10
produced after 24 h of exposure to these stimuli are mea-
sured with commercial ELISA kits. In a subset of patients,
also data from pre-market and commercial cellular tests
will be available. In addition, genome wide association
studies (GWAS) are performed on DNA extracts from
EDTA blood from the first consecutive 600 patients in-
cluded with erythema migrans, to identify associations be-
tween single-nucleotide polymorphisms (SNPs) and the
development of persistent symptoms, ex-vivo cytokine
production profiles, or other determinants assessed in this
study. Finally, in a selected subset of patients, gene expres-
sion profiling (microarray) is performed on skin biopsies
from the lesion and contralateral healthy skin as well as
on stimulated PBMCs.
From subjects in the unconfirmed Lyme borreliosis
control group, blood is collected at baseline only. These
controls are subjected to the same measurements as the
confirmed patients, with the exception of genetic ana-
lysis and skin biopsies, whereas for the population con-
trol group and the tick bite control group only
questionnaire data are obtained.
Outcome measures and data analysis
The primary outcome measure is the prevalence and se-
verity of persistent symptoms in patients with confirmed
Lyme borreliosis after treatment, assessed by standard-
ized questionnaires on fatigue, pain and neurocognitive
functioning. Persistent symptoms are defined as an im-
paired score for fatigue severity (CIS, subscale fatigue,
score 35 or higher), pain (SF-36, subscale pain, score 55
or lower), or impaired neurocognitive functioning (CFQ,
score 44 or higher), started within six months after treat-
ment for confirmed Lyme borreliosis, and lasting for at
least 6 months, as assessed by questionnaires adminis-
tered at baseline, and 3, 6, 9 and 12 months after inclu-
sion. Patients with scores exceeding the cutoff scores for
fatigue, pain or neurocognitive functioning during at
least six months are categorized as cases, i.e. Lyme bor-
reliosis patients with persistent symptoms. To correct
for baseline symptoms unrelated to Lyme borreliosis, the
prevalence of symptoms in the population control co-
hort and tick bite control cohort are used. Variability
and seasonality in scores on several questionnaires ob-
tained during one year are compared between patients
with confirmed Lyme borreliosis, the population control
group and the tick bite control group. A separate ana-
lysis is performed on patients with persistent symptoms
lasting less than 6 months.
Secondary outcome measures are potential microbio-
logical, immunological, genetic, clinical, cognitive-behav-
ioral, and epidemiological determinants of persistent
symptoms. The association of these parameters with de-
velopment of persistent symptoms is assessed by compar-
ing results of confirmed Lyme borreliosis patients with
persistent symptoms (cases) and without persistent symp-
toms (controls). Prediction rules for the risk and severity
of persistent symptoms for individual patients will be de-
veloped. Determinants for persistent symptoms identified
in patients with confirmed Lyme borreliosis are also
assessed in the unconfirmed Lyme borreliosis control
group in an exploratory manner.
Sample size
As mentioned above, the reported percentage of patients
developing persistent symptoms after treatment for
Lyme borreliosis varies widely from 0 to 48%. For the
present study, a prevalence of 5% is assumed, based on a
retrospectively estimated annual incidence rate of per-
sistent symptoms in patients with erythema migrans and
disseminated Lyme borreliosis in the Netherlands [2]. At
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a 5% prevalence of persistent symptoms for a cohort of
2000 patients, a 25% lower proportion for a determinant
can be detected in patients without symptoms, if present
in at least 57% of patients with persistent symptoms
(power 80%, alpha 5%). In a cohort of 1500 patients, a
25% lower proportion can be detected for a determinant
that is present in at least 66% of cases with persistence
of symptoms, and for a cohort of 1000 patients for one
that is present in at least 77% of cases (power 80%, alpha
of 5%). When the prevalence of persistent symptoms
would be higher, the power to detect these differences
increases.
Discussion
The LymeProspect study evaluates the prevalence and
severity of persistent symptoms after treatment for Lyme
borreliosis, and aims to identify determinants for these
symptoms. This study is the first to apply a prospective
design, investigating a broad range of hypotheses on the
etiology of persistent symptoms in a large cohort of pa-
tients with confirmed Lyme borreliosis. Previous studies
have described the prevalence of persistent symptoms
attributed to Lyme borreliosis in the United States and
in Europe. Several studies have reported associations be-
tween individual microbiological, immunological, gen-
etic, clinical and cognitive-behavioral factors and
persistent symptoms after treatment in specific groups
of patients. Firstly, persistence of Borrelia infection after
antibiotic treatment has been suggested as a cause of
persistent symptoms after treatment [34], although this
is difficult to detect with the current diagnostic tools,
and randomized trials have not found beneficial effects
of prolonged antibiotic treatment in patients with per-
sistent symptoms [35–38]. Other microbiological hy-
potheses include culture positivity, infection by specific
Borrelia burgdorferi s.l. genospecies or strains, and
co-infection with other tick-borne pathogens [39–42],
although there is no convincing evidence of long-term
infection with other tick-borne pathogens in patients
with persistent symptoms attributed to Lyme disease
[43]. Secondly, an ongoing aberrant immune response
and underlying genetic polymorphisms may play a role.
This has been specifically well-studied in patients with
antibiotic-refractory Lyme arthritis [44–46]. Furthermore,
several cytokines or cytokine profiles have been related to
persistence of symptoms after treatment for Lyme borre-
liosis [15, 47–50]. Thirdly, in a cognitive-behavioral
model, the persistence of symptoms was related to beliefs
and behavior of the patients in response to these symp-
toms. This model has been successfully applied to persist-
ent symptoms in other conditions [51, 52], and previous
studies have suggested that psychological factors could
play a role in functional outcome in patients with Lyme
borreliosis [10, 53]. Finally, clinical and epidemiological
factors could be associated with persistence of symptoms,
including age, clinical signs, co-morbidity, Lyme borrelio-
sis manifestation, duration of symptoms before start of
treatment, type of antibiotic treatment, and prior exposure
to tick bites or Borrelia infection [14, 54].
However, conclusions of previous findings vary widely
and are difficult to be generalized due to heterogeneity
in case definitions, antibiotic treatment regimes,
follow-up periods, control groups and primary out-
comes. The strengths of the current study are its size,
prospective approach, and explorative and multifaceted
design, enabling a thorough analysis of the prevalence
and determinants of persistent symptoms of Lyme bor-
reliosis in the Netherlands. The use of validated ques-
tionnaires with norm scores and the availability of
additional population and tick bite control groups will
allow to accurately compare the prevalence and severity
of symptoms in the patient cohort to the background
prevalence. The control groups will also allow correction
for development of non-specific symptoms over time
and their seasonal changes.
The majority of participants are expected to be diag-
nosed with erythema migrans and to be enrolled online.
To ascertain that subjects meet the inclusion criteria,
medical information about the diagnosis is obtained
from their physician in a standardized fashion, as well as
a photograph of the skin lesions, which will be evaluated
by independent experts. Serological evaluation at two
time points could further contribute to the confirmation
of active Lyme borreliosis. For patients who are enrolled
through the clinical Lyme expertise centers and have
consented to skin biopsy, B. burgdorferi s.l. culture and
qPCR on skin biopsies for B. burgdorferi s.l. will enable
further laboratory confirmation of the diagnosis.
Patients are encouraged to provide baseline blood
samples before initiation of antibiotic therapy. To assess
a potential effect of antibiotic treatment on microbio-
logical and immunological endpoints, duration of prior
treatment will be explored in sensitivity analyses. We
have ruled out a significant effect of overnight shipping
of blood samples on immunological outcomes in prior
pilot studies (unpublished data).
The primary outcome measure has been defined as
the presence of fatigue (CIS), pain (SF-36) and/or neuro-
cognitive complaints (CFQ) presenting within six
months after initial diagnosis and treatment, and lasting
for at least six months. Fatigue, pain and neurocognitive
complaints have been reported as major symptoms re-
ported after Lyme borreliosis, and constitute the defin-
ition of PTLDS. Repeated assessment of symptoms every
three months during one year of follow-up will enable to
assess the time course of symptoms, and to detect disab-
ling symptoms lasting shorter than six months as well.
Furthermore, the impact of symptoms on general
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functioning, as measured by physical and social func-
tioning, health-care use and absenteeism at work, is
assessed. Subjects experiencing symptoms, or those pre-
occupied with Lyme borreliosis, could be more inclined
to fill in questionnaires at baseline and to complete the
follow-up, possibly leading to selection bias. This under-
scores the importance of the comparison of our primary
outcomes in the patient cohort with the various control
groups, since all three groups have the same scheme of
follow-up and risk of bias.
In conclusion, the LymeProspect study is expected to
provide additional insights into the prevalence and se-
verity of persistent symptoms after antibiotic treatment
for Lyme borreliosis. In addition, the study will identify
determinants for persistent symptoms. These findings
may lead to the development of prediction models for
individual patients and may guide future research on
preventive and therapeutic strategies of persistent symp-
toms after treatment for Lyme borreliosis.
Additional file
Additional file 1: Table S1. Clinical and laboratory criteria for inclusion
of patients with confirmed Lyme borreliosis. Clinical and laboratory
inclusion criteria for patients with confirmed Lyme borreliosis are
described in detail. Criteria are largely based on case definitions
published by Stanek et al. and alternative causes for symptoms should be
excluded by the primary caregiver 4. *The CXCL-13 cut-off value is
laboratory dependent. #As determined by neurological assessment or
electromyogram. ^Preferably through synovial fluid puncture or synovium
biopsy. %After a cardiologist has been consulted. (DOCX 17 kb)
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